OR WAIT null SECS
Editor of Pharmaceutical Technology Europe
Certain therapeutics, such as ophthalmics, must be provided as a sterile dosage form but can pose fill/finish challenges due to the small batch sizes required and the fact that the products used are difficult to fill and of high value.
Sterile fill/finish manufacturing is expected to experience significant growth over the coming years, with some market research analysts predicting the field to be worth $12.1 billion by 2025 (1). Expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require sterile production, form part of the driving force for this rising demand for fill/finish services.
Ophthalmic therapeutics, in particular, require heightened expertise due to the fact that they are administered to the eyes, which are extremely sensitive and important organs. To learn more about the intricacies of sterile fill/finish manufacturing, specifically pertaining to ophthalmics, Pharmaceutical Technology spoke with Daniel Kehl, chief executive officer at swissfillon—a fill/finish specialist based in Switzerland.
Felicity Thomas is the European editor for Pharmaceutical Technology Group.
eBook: Biologics and Sterile Drug Manufacturing, May 2021
When referring to this article, please cite it as F. Thomas, “Eyeing Up Success in Fill/Finish,” Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).